New combo therapy aims to boost breast cancer treatment before surgery

NCT ID NCT07506876

First seen Apr 02, 2026 · Last updated May 21, 2026 · Updated 2 times

Summary

This study is for adults with a certain type of breast cancer (HER2-positive and hormone receptor-positive). It tests whether adding hormone therapy to the usual chemotherapy and HER2-targeted therapy before surgery can improve how well the tumor shrinks. About 30 participants will receive this combined treatment, and their results will be compared to past patients who did not get the hormone therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER - INFILTRATING DUCTAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Legacy Good Samaritan Medical Center

    RECRUITING

    Portland, Oregon, 97210, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Legacy Meridian Park Medical Center

    RECRUITING

    Tualatin, Oregon, 97062, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Legacy Mount Hood Medical Center

    RECRUITING

    Gresham, Oregon, 97030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Legacy Salmon Creek Medical Center

    RECRUITING

    Vancouver, Washington, 98686, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.